179 related articles for article (PubMed ID: 34348346)
1. Oxaliplatin and 5-Fluorouracil in Advanced Well-Differentiated Digestive Neuroendocrine Tumors: A Multicenter National Retrospective Study from the French Group of Endocrine Tumors.
Girot P; Baudin E; Senellart H; Bouarioua N; Hentic O; Guimbaud R; Walter T; Ferru A; Roquin G; Cadiot G; Pracht M; Girot JB; Malka D; Ducreux M; Bennouna J; Matysiak-Budnik T; Hadoux J; Touchefeu Y
Neuroendocrinology; 2022; 112(6):537-546. PubMed ID: 34348346
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors.
Oziel-Taieb S; Zemmour C; Raoul JL; Mineur L; Poizat F; Charrier N; Piana G; Cavaglione G; Niccoli P
Anticancer Res; 2021 Apr; 41(4):2071-2078. PubMed ID: 33813416
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
Al-Toubah T; Morse B; Pelle E; Strosberg J
Oncologist; 2021 Feb; 26(2):115-119. PubMed ID: 33225478
[TBL] [Abstract][Full Text] [Related]
4. Oxaliplatin-Based Chemotherapy in Advanced Neuroendocrine Tumors: Clinical Outcomes and Preliminary Correlation with Biological Factors.
Spada F; Antonuzzo L; Marconcini R; Radice D; Antonuzzo A; Ricci S; Di Costanzo F; Fontana A; Gelsomino F; Luppi G; Nobili E; Galdy S; Cella CA; Sonzogni A; Pisa E; Barberis M; Fazio N
Neuroendocrinology; 2016; 103(6):806-14. PubMed ID: 26789262
[TBL] [Abstract][Full Text] [Related]
5. Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer.
Faure M; Niccoli P; Autret A; Cavaglione G; Mineur L; Raoul JL
Mol Clin Oncol; 2017 Jan; 6(1):44-48. PubMed ID: 28123727
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Toxicity of 5-Fluorouracil-Oxaliplatin in Gastroenteropancreatic Neuroendocrine Neoplasms.
Merola E; Dal Buono A; Denecke T; Arsenic R; Pape UF; Jann H; Wiedenmann B; Pavel ME
Pancreas; 2020 Aug; 49(7):912-917. PubMed ID: 32658073
[TBL] [Abstract][Full Text] [Related]
7. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma.
Hadoux J; Malka D; Planchard D; Scoazec JY; Caramella C; Guigay J; Boige V; Leboulleux S; Burtin P; Berdelou A; Loriot Y; Duvillard P; Chougnet CN; Déandréis D; Schlumberger M; Borget I; Ducreux M; Baudin E
Endocr Relat Cancer; 2015 Jun; 22(3):289-98. PubMed ID: 25770151
[TBL] [Abstract][Full Text] [Related]
8. FOLFOX-bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors.
Lacombe C; Perrier M; Hentic O; Brixi H; De Rycke O; Cros J; Rebours V; Cadiot G; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Jan; 35(1):e13227. PubMed ID: 36599808
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
10. Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.
Kunz PL; Balise RR; Fehrenbacher L; Pan M; Venook AP; Fisher GA; Tempero MA; Ko AH; Korn WM; Hwang J; Bergsland EK
Pancreas; 2016 Nov; 45(10):1394-1400. PubMed ID: 27171514
[TBL] [Abstract][Full Text] [Related]
11. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
Collot T; Fumet JD; Klopfenstein Q; Vincent J; Bengrine L; Ghiringhelli F
Anticancer Res; 2018 Oct; 38(10):5963-5968. PubMed ID: 30275226
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
de Mestier L; Lamarca A; Hernando J; Zandee W; Alonso-Gordoa T; Perrier M; Walenkamp AM; Chakrabarty B; Landolfi S; Van Velthuysen MF; Kats-Ugurlu G; Caminoa A; Ronot M; Manoharan P; Garcia-Alvarez A; Brabander T; García Gómez-Muriel MI; Cadiot G; Couvelard A; Capdevila J; Pavel ME; Cros J
Endocr Relat Cancer; 2021 Jun; 28(8):549-561. PubMed ID: 34061764
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the combination of oxaliplatin and 5-fluorouracil or gemcitabine in patients with sporadic metastatic pulmonary carcinoid tumors.
Walter T; Planchard D; Bouledrak K; Scoazec JY; Souquet PJ; Dussol AS; Guigay J; Hervieu V; Berdelou A; Ducreux M; Arpin D; Lombard-Bohas C; Baudin E
Lung Cancer; 2016 Jun; 96():68-73. PubMed ID: 27133753
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
George TJ; Ali A; Wang Y; Lee JH; Ivey AM; DeRemer D; Daily KC; Allegra CJ; Hughes SJ; Fan ZH; Cameron ME; Judge AR; Trevino JG
Oncologist; 2021 Oct; 26(10):825-e1674. PubMed ID: 34101295
[TBL] [Abstract][Full Text] [Related]
17. Poorly differentiated neuroendocrine rectal carcinoma with uncommon immune-histochemical features and clinical presentation with a subcutaneous metastasis, treated with first line intensive triplet chemotherapy plus bevacizumab FIr-B/FOx regimen: an experience of multidisciplinary management in clinical practice.
Bruera G; Giuliani A; Romano L; Chiominto A; Di Sibio A; Mastropietro S; Cosenza P; Ricevuto E; Schietroma M; Carlei F;
BMC Cancer; 2019 Oct; 19(1):960. PubMed ID: 31619203
[TBL] [Abstract][Full Text] [Related]
18. Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer: A Randomized Clinical Trial.
Yu J; Gao Y; Chen L; Wu D; Shen Q; Zhao Z; Liu W; Yang H; Zhang Q; Wang X; Hu P; Zheng Z; Wang X; Liu H; Xu Z; Yan Z; Wu Y; Jin M; Zhang Q; Liu X; Zhu K; Shou C
JAMA Netw Open; 2022 Feb; 5(2):e220426. PubMed ID: 35226081
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-Containing Regimen.
Yoo C; Kim BJ; Kim KP; Lee JL; Kim TW; Ryoo BY; Chang HM
Cancer Res Treat; 2017 Jul; 49(3):759-765. PubMed ID: 27857025
[TBL] [Abstract][Full Text] [Related]
20. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
